Continuing Review - PowerPoint PPT Presentation

Loading...

PPT – Continuing Review PowerPoint presentation | free to download - id: 6e5891-MzI0N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Continuing Review

Description:

Title: Continuing Review Subject: Continuing Review Author: Karen Jeans, MSN, CCRA, CCRN Keywords: Continuing Review Last modified by: vhacowyblea Created Date – PowerPoint PPT presentation

Number of Views:17
Avg rating:3.0/5.0
Date added: 2 May 2020
Slides: 22
Provided by: KarenJ165
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Continuing Review


1
Continuing Review
  • Presented by
  • Karen Jeans, PhD, CCRN, CIP
  • Program Analyst, COACH

2
Objectives
  • Describe what is meant by continuing review
  • Describe VA requirements for continuing review
  • Calculate dates for continuing review expiration

3
What is Meant by Continuing Review?
  • Term is undefined in the Federal Regulations

4
What is Continuing Review?
  • Monitoring on-going projects thru continuing
    review at intervals appropriate to the degree of
    risk, but not less than once per year.
  • VHA Handbook 1200.05, Paragraph 7.(g) page 15
  • An IRB shall conduct continuing review of
    research covered by these regulations at
    intervals appropriate to the degree of risk, but
    not less than once per year . . .
  • 21 CFR 56.109(f) and 38 CFR 16.109(e)

5
Criteria for IRB Approval (.111)
  • Required determinations
  • Risks to subjects are minimized
  • By using procedures consistent with sound
    research design
  • When appropriate, using procedures already being
    performed
  • Risks are reasonable in relation to benefits
  • Selection of subjects is equitable
  • Informed consent will be sought prospectively
  • Informed consent is appropriately documented
  • Research plan makes adequate provisions for
    safety monitoring
  • There are adequate provisions to protect privacy
    and confidentiality
  • B. When appropriate, additional protections for
    Vulnerable Subjects

6
Continuing Review
  • Decisions Made by the IRB at Continuing Review
  • Are subjects adequately protected through the
    current approved protocol?
  • Informed consent issues
  • The informed consent process is appropriate
  • Written informed consent document is accurate and
    complete
  • Any significant new findings are provided to the
    subject

7
Continuing Review
  • What is required to be submitted to the IRB by a
    Principal Investigator at Continuing Review?

8
Continuing Review VHA Handbook 1200.05
Requirements
  • Brief summary of the research methodology and
    procedures
  • Number of subjects entered and withdrawn
    (including the reason for withdrawal) for the
    review period and since the inception of the
    research project
  • The gender and minority status of those entered
    into the protocol
  • Number of subjects considered as members of
    specific vulnerable populations
  • A copy of the proposal and all approved
    amendments
  • A copy of the current consent document for the
    IRB to review
  • A copy of the current HIPAA Authorization
    document, if separate from the informed consent

9
Continuing Review VHA Handbook 1200.05
Requirements
  • Information that may impact on the risk benefit
    ratio such as AEs, unanticipated problems, and
    complaints regarding the research
  • Research findings to date, if available
  • Summary of the DSMB or DMC meetings (if
    applicable) or findings based on information
    collected by the data and safety monitoring plan
    submitted in the initial proposal
  • An assurance that all SAEs and UAEs have been
    reported as required and
  • New scientific findings in the literature, or
    other relevant findings, that may impact on the
    research.

10
Continuing Review Lapses in IRB Approval - VHA
Handbook 1200.05
  • If the continuing review does not occur within
  • the timeframe set by the IRB, the research
    is
  • automatically suspended.
  • NOTE For suspended research, enrollment for
  • new subjects cannot occur continuation of
  • research interventions or interactions in
    already
  • enrolled subjects should only continue when
    the
  • IRB or IRB Chair, in consultation with the
    Chief
  • of Staff (COS), finds that it is in the best
  • interest of individual subjects to do so.

11
Continuing Review Lapses in IRB Approval - VHA
Handbook 1200.05
  • Once notified of the suspension, the PI must
  • immediately submit to the IRB Chair, a list
    of
  • research subjects for whom suspension of the
  • research would cause harm. The IRB Chair,
    with
  • appropriate consultation with the Chief of
    Staff,
  • determines if the subject may continue in the
  • research.
  • If the study is FDA-regulated, the Chief of
    Staff
  • and IRB Chair must follow FDA requirements
    in
  • 21 CFR 56.108(b)(3) in making their
    decision.

12
Continuing Review VHA Handbook 1200.05
  • Whose responsibility is it to make sure a
    protocol does not lapse?
  • Both the Investigator and IRB have different
  • roles

13
Continuing Review VHA Handbook 1200.05
  • Notification of Lapse of Approval
  • Sponsoring agent, private sponsor, ORD, ORO, or
    other Federal agencies must be informed, as
    appropriate
  • When is it appropriate to notify these agencies?

14
Continuing Review VA vs. Everyone Else
  • What is the difference between a lapse in
  • approval and a suspension of IRB approval?
  • A lapse in approval is a passive process.
  • A suspension of IRB approval is an active
  • process.

15
Lapse of Approval Following Expiration of
Continuing Review Interval
  • Issue 1 What about the investigational
    pharmacist?
  • Issue 2 What happens to subjects entered into a
    study
  • during a period when the studys
    continuing review approval period lapsed?
  • Issue 3 What happens to subjects enrolled
    during a period when the studys continuing
    review approval lapsed and it was due to an
    administrative error within the IRB (study
    requiring review by a convened IRB left off
    the agenda)?

16
Determination of Continuing Review Dates
  • When Does Continuing Review Expire?
  • The convened IRB meets on March 1, 2007 and
    approves Study A for a continuing review period
    of one year pending minor revisions. The
    revisions are approved by expedited review of the
    IRB Chairperson on March 7, 2007.
  • The convened IRB meets on March 1, 2006 and
    approves Study B for a continuing review period
    of one year pending major revisions. The
    revisions are reviewed and approved by a convened
    IRB on April 1, 2006.

17
Determination of Continuing Review Dates
  • Continued
  • The convened IRB meets on March 1, 2005 and
    approves Study C for a continuing review period
    of one year pending major revisions. The
    revisions are reviewed and approved by a convened
    IRB on March 1, 2007.
  • The convened IRB meets on March 1, 2006 and
    approves Study D for a continuing review period
    of one year pending minor revisions. The
    revisions are reviewed and approved by a convened
    IRB (the IRB does not allow expedited review
    procedures) on April 1, 2007.

18
Annual Revision Date Keeping the Same Date
  • If continuing review occurs annually, and the IRB
    performs the continuing review evaluation 30 days
    before the IRB approval period expires, the IRB
    may retain the anniversary as the date by which
    the continuing review must occur.

19
Annual Revision Date Keeping the Same Date
  • The IRB approves a protocol requiring full board
    review on March 1, 2006. Continuing review
    expires on March 1, 2007.
  • 2. The convened IRB reviews the protocol for
    continuing approval on February 15, 2007 and
    approves the study for one year. Continuing
    review expires on March 1, 2008.
  • 3. The convened IRB reviews the protocol on
    January 27, 2008 and approves the study for one
    year. Continuing review expires on January 27,
    2009.

20
Guidance on Continuing Review
  • Office for Human Research Protections
  • Guidance on Continuing Review dated January 15,
    2007
  • http//www.hhs.gov/ohrp/humansubjects/guidance/con
    trev0107.htm

21
QUESTIONS
About PowerShow.com